Medtronic lifts FY27 guidance on broad growth across portfolio
Sep 1, 2026, 6:50 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The combination of an above-guidance quarter, a raised full-year outlook, and multiple growth catalysts (Affera, Cornerstone Robotics, Pi-Cardia) supports a higher multiple and potential near-term price appreciation. Historical precedent shows MDT stock reacting positively to sustained guidance upgrades and material portfolio wins, though execution risk and diabetes separation remain watch items.
AI summary
What happened, with direct paths to the underlying reporting
Medtronic delivered a strong Q1 FY27, with revenue of $9.756B and 13.7% organic growth, prompting a raised FY27 target of 7.25–7.75% and EPS guidance of $5.94–$6.00. Growth was broad-based across cardiovascular, neuroscience, and medical-surgical platforms, complemented by new growth initiatives (Affera CE Mark expansion, Sphere-9 catheter) and strategic bets in robotics and leaflet technology, signaling durable upside into 2027 and beyond.
Q1 FY27 revenue $9.756B, up 13.7% (organic 13.7%), vs guidance.
Raised FY27 organic revenue growth to 7.25%–7.75% and non-GAAP EPS to $5.94–$6.00.
Cardiovascular grew 18.9%; CRM up 15%, Ablation Solutions up 88% (organic).
Announced CE Mark expansion for Affera Mapping/Ablation and Sphere-9 catheter.
Strategy bets: Cornerstone Robotics partnership, Pi-Cardia investment; two acquisitions completed.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Medtronic posted an earnings beat with adjusted EPS of $1.55 and revenue of $9.81B, up 9.9%. Cardiovascular sales rose 13.8% YoY to $3.80B, bolstering growth momentum. BTIG upgrad…
Medtronic delivered strong Q4 and full-year 2026 results, beating revenue and earnings expectations. Growth was driven by cardiac ablation, diabetes, and medical-surgical products…
Medtronic beat Q4 revenue and adjusted earnings estimates, driven by steady demand for its heart devices used in complex cardiac procedures. The result signals resilience in the c…
Medtronic is set to acquire SPR Therapeutics for about $650 million, which will enhance its neuromodulation portfolio by integrating temporary PNS technology. This move aims to bo…
